HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

NOW APPROVED For moderate to severe rheumatoid arthritis (RA) in adult MTX-IR patients1

Defy expectations

RINVOQ met ALL primary (ACR20 or ACR50 at Week 12 or 14) and ranked secondary endpoints in 5 clinical trials.1,2

ACR=American College of Rheumatology; IR=tolerance or inadequate response; MTX=methotrexate

In clinical trials, RINVOQ met all primary and ranked
secondary endpoints2

28
52*
41
68*
36
64*
28
65*
36
71*

SELECT-EARLY
(Study RA‑I):1,3

48‑week, randomized, double‑blind, active comparator‑controlled study of 947 adult patients with moderate to severe RA who were MTX‑naïve.

SELECT-MONOTHERAPY
(Study RA-II):1,4

14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT-NEXT
(STUDY RA-III)1,5

12‑week, randomized, double‑blind, placebo‑controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

SELECT-BEYOND
(Study RA‑V):1,6

12‑week, randomized, double‑blind, placebo‑controlled study of 499 adult patients with moderate to severe RA who have had an inadequate response or intolerance to bDMARDs.

SELECT-COMPARE
(Study RA‑IV):1,7

48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

RINVOQ is a once-daily JAK inhibitor

Head-to-Head results vs HUMIRA® (adalimumab)+MTX7

In SELECT-COMPARE, RINVOQ + MTX demonstrated superiority in ACR50,
HAQ‍-‍DI, and pain reduction at Week 12

Durable remission, even without MTX1,8,9

DAS28-CRP<2.6 at Week 12 or 14, with durable remission rates up to ~1 year

Radiographic inhibition, even without MTX1

∆mTSS at Week 24 or 26*

*RINVOQ is not indicated for
MTX-naïve patients

Safety data from a large registrational program In RA

5 phase 3 trials with >4350 patients across treatment arms and >3400 patient‑years of exposure to RINVOQ 15mg

Commitment to exceptional access and patient support

Resources to help patients prescribed RINVOQ

 

RINVOQ 15 mg; upadacitinib 30 mg; methotrexate; HUMIRA (adalimumab); placebo
Long-term data as of November 14, 2018

ACR=American College of Rheumatology; DAS28-CRP= Disease Activity Score, 28 Joints, C-reactive protein (CRP) variant; HAQ-DI=health assessment questionnaire disability index; JAK=janus kinase; MTX=methotrexate; ∆mTSS=change from baseline in modified total Sharp score

See how UPADAC Complete provides an exceptional access
and patient support experience

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking